Status:
COMPLETED
AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients
Lead Sponsor:
Technische Universität Dresden
Conditions:
Leukemia, Nonlymphoblastic, Acute
Eligibility:
All Genders
16+ years
Phase:
PHASE4
Brief Summary
The AML96 study examines the feasibility of a risk-adapted postremission treatment strategy including related and unrelated allogeneic stem cell transplantation for high risk AML patients and related ...
Detailed Description
The AML96 study examines the feasibility of a risk-adapted postremission treatment strategy including related and unrelated allogeneic stem cell transplantation for high risk AML patients and related ...
Eligibility Criteria
Inclusion
- de novo or secondary acute myeloid leukemia of the FAB subtypes M0-M2 and M4-M7
- de novo or secondary myelodysplastic syndrome FAB subtypes RAEB and RAEB-T
- written informed consent
Exclusion
- severe comorbidities
- severe uncontrolled complications of the leukemia
- previous therapy of leukemia/MDS
- HIV-Infection
- known relevant allergy against study medication
- pregnancy
- missing written informed consent
Key Trial Info
Start Date :
February 1 1996
Trial Type :
INTERVENTIONAL
End Date :
November 1 2008
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00180115
Start Date
February 1 1996
End Date
November 1 2008
Last Update
July 17 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Department I, University Hospital Carl Gustav Carus
Dresden, Germany, 01307